Categories
Change Password!
Reset Password!
A randomized controlled study aimed to investigate whether a mouthwash with β-cyclodextrin–citrox mouthwash (CDCM) can minimize the viral load in the saliva.
The study favors the significance
of using CDCM on day 1 (four hours following the initial dose) for minimizing
coronavirus viral load in the saliva. For the long-term effect (seven days),
CDMC seems to offer a little benefit than placebo in decreasing SARS-CoV-2 load
in saliva.
A randomized controlled study aimed
to investigate whether a mouthwash with β-cyclodextrin–citrox mouthwash (CDCM)
can minimize the viral load in the saliva.
This multicentre, double-blind study enrolled RT-PCR-positive people (age 18-85 years) having asymptomatic to mild symptoms of coronavirus disease for <8 days. A total of 176 eligible adults were randomized to either the CDCM group or placebo group.
For seven
days, 3 rinses daily were done. On the first day, saliva sampling was carried out at 09.00
(T1), 13.00 (T2) and 18.00 (T3). On the following six days, 1 sample was taken
at 15.00. For viral detection, quantitative RT-PCR was utilized.
As per intention-to-treat assessment, CDCM showed superior efficacy over the course of 1 day when compared to placebo four hours following the initial dose, with a median percentage (log10copies/mL) reduction T1-T2 of -12.58%. In comparison with placebo (3.31 log10copies/mL), the low median value for the CDCM (3.08 log10copies/mL) was maintained by the 2nd dose.
On the seventh day, a greater median percentage (log10copies/mL) decline in salivary SARS-CoV-2 load was reported in CDCM group vs. placebo group, as shown in Table 1:
These outcomes were verified by the per-protocol assessment.
In people having mild or asymptomatic
coronavirus disease, CDCM (4 hours after the initial dose) exhibited a favorable effect in
decreasing salivary viral load. For the long-term effect, the benefit to
suggest CDMC seems to be limited, even if 3 daily rinses displayed a positive
impact on decreasing the viral load in saliva seven days following the initial
intake in people with high salivary SARS-CoV-2 load at the baseline.
Clinical Microbiology and Infection
Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial
Florence Carrouel et al.
Comments (0)